Shares of Akers Biosciences Inc. (AKER) are currently spiking over 40% after announcing a merger deal with MyMD Pharmaceuticals, Inc.
AKER is trading at $2.43, up $0.71 or 41.28%, on the Nasdaq.
Akers' shareholders will own around 20% of the combined company, while MyMD's shareholders will own around 80%. The merger is expected to close in the first half of 2021.
Following the deal, the two companies will develop and sell MyMD's novel immunotherapy pipeline assets, including MYMD-1, a first-in-class drug being developed to treat autoimmune and age-related diseases.
MyMD intends to also continue to develop its second asset, SUPERA-1R, a drug platform based on a patent-protected, synthetic derivative of cannabidiol that seeks to target key cannabinoid receptor.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.